Skip to main content

GV20 Oncotherapy Closes Series B for Genomics/AI-based mAb Portfolio

GV20 Oncotherapy, a Cambridge , MA - Shanghai biotech, completed a Series B round of undisclosed size to advance its lead immuno-oncology antibody candidate into the clinic. GV20 claims unique expertise in novel target identification and antibody drug discovery in the immuno-oncology field. The company applies its novel genomics platform and AI techniques to speed up antibody drug discovery. The B round was led by Coatue Management, and included existing investors IDG Capital, 3W Investment, Watson Capital, Linear Capital and others. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.